Insulet Corporation (PODD) — Analysis Summary
Insulet Corporation (PODD) has a market cap of $11.23B with year-over-year revenue growth of +30.7%. Net margin stands at 9.1%. The stock trades at a P/E ratio of 37.1.
Key Takeaways
- Revenue changed +30.7% year-over-year
- Net margin of 9.1%
- P/E ratio of 37.1
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, PODD posted revenue growth of +30.7% and trades at a P/E of 37.1.
Insulet Corporation (PODD)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
5,400
Headquarters
ACTON, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.